Clinical Trial

With a landmark NEJM publication and FDA approval, Rhythm Pharma's setmelanotide offers hope for a rare obesity, proving a potent strategy for niche markets.

With a new name and $35M in fresh funding, Allotera Therapeutics is doubling down on a pivotal trial for Sofi-cel, a therapy aimed at solving a tough T-cell cancer.

With a PDUFA date set, Arcutis' ZORYVE could soon offer a once-daily, non-steroidal cream for infants, addressing a massive unmet need for families.

With bladder cancer recurrence rates stubbornly high, UroGen Pharma is advancing a novel oncolytic virus into human trials. Can it finally break the cycle?

Keenova Therapeutics' positive Phase 3 results for XIAFLEX could bring the first-ever approved drug for plantar fibromatosis, a painful, disabling condition.

Clinical-stage Nyra Medical begins a key U.S. study for its novel mitral valve device, a strategic move challenging established players in a crowded field.

As OKYO Pharma woos investors with a promising eye drug, it carries the hopes of patients with debilitating pain. A look at the science, stakes, and systems.

HMNC Brain Health's new oral ketamine shows promise by minimizing side effects, but an unmet endpoint raises questions. Is this the key to at-home TRD care?

The FDA has fast-tracked mitapivat for sickle cell disease, offering new hope for patients. But a closer look reveals the high stakes of this strategy.

With €33M in new funding, Cyllene Therapeutics is advancing a novel gene therapy using HSV-1 vectors. Could this be the one-shot cure for millions?

Vivos Inc. wins FDA approval for a human trial of RadioGel®, a targeted therapy that could offer new hope for patients with non-resectable thyroid cancer.

With a new ADC expert as CMO, Corbus Pharmaceuticals is advancing its dual pipeline. This move signals a critical phase for its cancer drug and obesity therapy.

IceCure's ProSense™ is reshaping oncology in Brazil. A US FDA approval provided a critical tailwind, validating a less invasive future for cancer care.

A South Korean biotech's diabetes drug finds new purpose in fighting FSHD, backed by a foundation's innovative funding model that could reshape rare disease R&D.

Australian biotech Immuron hires a top dealmaker to land a partner for its novel C. diff therapy. The goal: secure funding and unlock a potential $400M market.

UK biotech Ananda Pharma advances its MRX1 drug to Phase 2 trials, targeting a debilitating chemotherapy side effect with no current effective treatment.

Immunomic Therapeutics begins human trials for ITI-9001, an saRNA vaccine aiming to rewrite the immune response to Japanese cedar pollen allergy.

Cerezen, a non-invasive device shown to reverse cognitive decline, has EU approval but remains in FDA limbo, raising questions about US patient access.

NKGen Biotech signals a strategic pivot to Asia, leveraging its novel NK cell therapy, troculeucel, to tap into China's new, accelerated biotech pathways.

Revolution Medicines' zoldonrasib delivers high response rates in trials for RAS G12D pancreatic cancer, offering a beacon of hope against a lethal disease.